Optimal Treatment for Recurrent Clostridium Difficile
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by
taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the
treatment of recurrent Clostridium difficile infection.